

TABLE E-1 Radiographic Scores and Healing Rates in Study 1 and Study 2 at Twelve Weeks

Groups	Healing Rate (no. healed/total no.)	Radiographic Score*
Study 1		
Control	0/15	2.9 ± 0.8
Continuous (0-12 wk) Scl-Ab treatment	4/15	3.8 ± 0.8†
Early (0-2 wk) Scl-Ab treatment	3/15	3.4 ± 0.9
Delayed (2-4 wk) Scl-Ab treatment	4/15	3.5 ± 0.9
Study 2		
Control	0/15	2.4 ± 0.7
Continuous (0-12 wk) Scl-Ab treatment	0/15	3.2 ± 0.8‡

*The values are given as the mean and the standard deviation. †P < 0.05 vs. control in Study 1. ‡P = 0.0038 vs. control in Study 2.

TABLE E-2 Micro-CT Analysis of the Femoral Defects in Study 1 and Study 2 at Twelve Weeks

Groups	Bone Volume* (mm ³)	Bone Volume Fraction* (%)
Study 1		
Control	18.3 ± 8.6	39.3 ± 15.3
Continuous (0-12 wk) Scl-Ab treatment	29.7 ± 11.2	60 ± 17†
Early (0-2 wk) Scl-Ab treatment	22.7 ± 14.8	44.4 ± 20
Delayed (2-4 wk) Scl-Ab treatment	25.7 ± 16.5	49.6 ± 20.4
Study 2		
Control	8.5 ± 3.3	19.2 ± 9.5
Continuous (0-12 wk) Scl-Ab treatment	17.6 ± 7.4‡	37.4 ± 0.1‡

*The values are given as the mean and the standard deviation. †P < 0.05 vs. control in Study 1. ‡P < 0.001 vs. control in Study 2.

TABLE E-3 Histomorphometric Analysis

Groups	Bone Area* (mm ²)	Bone Area/Tissue Area* (%)
Study 1		
Control	30.3 ± 8.8	37.3 ± 10.2
Continuous (0-12 wk) Scl-Ab treatment	46.8 ± 16.2	44.4 ± 9.1
Early (0-2 wk) Scl-Ab treatment	31.4 ± 20.1	33.5 ± 13.5
Delayed (2-4 wk) Scl-Ab treatment	36 ± 17.4	40.4 ± 15
Study 2		
Control	13.1 ± 9.6	15.2 ± 9.1
Continuous (0-12 wk) Scl-Ab treatment	38.6 ± 23.8	28.2 ± 10.9

*The values are given as the mean and the standard deviation. No significant difference was detected between the controls and Scl-Ab groups in Study 1 and Study 2.